Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) had its price objective decreased by JMP Securities from $23.00 to $14.00 in a research note issued to investors on Thursday morning,Benzinga ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) shares reached a new 52-week low during trading on Friday after JMP Securities lowered their price target on the stock from $23.00 to $14 ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

JOTROL is designed to overcome the historical challenges of resveratrol by significantly enhancing bioavailability while minimizing gastrointestinal side effects. The upcoming Phase 2a trial will ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...